Dusseldorf - Delayed Quote EUR

Sosei Group Corp (JSS.DU)

5.30

0.00

(0.00%)

As of 12:31:10 PM GMT+2. Market Open.

Nxera Pharma Announces Appointments to its Executive Leadership Team

Mr. Kiyoshi Kaneko appointed as Chief Commercial Officer, and Ms. Mariko Nakafuji promoted to Chief Legal Officer Tokyo, Japan and Cambridge, UK, 1 April 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces two new appointments to its Leadership team: Mr. Kiyoshi Kaneko, is appointed as Chief Commercial Officer (CCO), and Ms. Mariko Nakafuji is promoted into the role of Chief Legal Officer (CLO). Mr. Kaneko brings experience in business development, corporate strate

GlobeNewswire 23 days ago

SOLTF
Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder

Tokyo, Japan and Cambridge, UK, 25 March 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a potent, selective and orally available mGluR5 negative allosteric modulator (NAM), for the treatment of alcohol use disorder (Clinical Trial ID: NCT06648655). The full announcement from Tempero Bio can be found by clicking here, in which Tempero Bio also announces the close of a $70 million financing,

GlobeNewswire 30 days ago

SOLTF
Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan

Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomniaFiling of daridorexant in Taiwan planned for 2025, and launch, if approved, is expected during 2026Daridorexant is launched in Japan as QUVIVIQ™ and is in Phase 3 trials in South Korea Tokyo, Japan and Cambridge, UK, 28 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has entered a license, supply

GlobeNewswire last month

SOLTF
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris

Cenerimod is a novel oral S1P1 receptor modulator with potential to be a first- or best-in-class therapy for multiple autoimmune diseasesViatris previously acquired rights to cenerimod in all other territories from Idorsia, and now has exclusive global rightsNxera will receive an upfront payment of US$10 million from Viatris, and is eligible to receive a further milestone payment upon regulatory approval of cenerimod in Japan plus royalties on net sales in the assigned territories Tokyo, Japan a

GlobeNewswire last month

SOLTF
Nxera Pharma Proposes Changes to its Board of Directors

Ms. Naoko Shimura and Ms. Nicola Rabson nominated for appointment as new External DirectorsMr. Shinichi Tamura, Mr. Tomohiro Tohyama and Mr. Kuniaki Kaga to retire from the Board of Directors Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its Board of Directors approved the change of Directors as stated below. The nomination of candidates for External Directors is based on the resolution of the Nomination Commit

GlobeNewswire 2 months ago

SOLTF
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and 12 months ended 31 December 2024. The full report can be viewed here. Chris Cargill, President & CEO of Nxera, commented: “2024 was a transformational year for Nxera during which we made excellent progress under our new company name and brand towards becoming a leading technology

GlobeNewswire 2 months ago

SOLTF
Nxera Pharma Webinar Presentation for FY2024 Financial Results

Tokyo, Japan and Cambridge, UK, 23 January 2025 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the year ended 31 December 2024 on Friday, 14 February 2025. The Company will host a live webinar presentation with Chris Cargill, President and CEO, Hironoshin Nomura, CFO, Matt Barnes, President of Nxera Pharma UK and Head of UK R&D and Makoto Sugita, President of Nxera Pharma Japan and Chief Medical Officer, at 5:00 pm JST (8:00 a

GlobeNewswire 2 months ago

SOLTF
Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio

Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”) regarding the clinical development of its partnered muscarinic agonist portfolio. These updates were presented by Neurocrine at the 43rd Annual J.P. Morgan Healthcare Conference. The update presented by Neurocrine included the following information: An End of Phase 2 meeting for NBI-1117568 (NBI-’5

GlobeNewswire 3 months ago

SOLTF
Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Tokyo, Japan and Cambridge, UK, 20 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Chris Cargill, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, 15 January 2025 at 3:00 p.m. PST. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. Presentation slides will b

GlobeNewswire 4 months ago

SOLTF
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia

Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Shionogi & Co., Ltd. (“Shionogi”) today announce that QUVIVIQ™ (daridorexant) 25 and 50 mg has been launched and is now available in Japan as a new treatment for adults with insomnia. QUVIVIQ™ is an oral Dual Orexin Receptor Antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting ne

GlobeNewswire 4 months ago

SOLTF
Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomniaQUVIVIQ™ (daridorexant) 25 and 50 mg was recently approved and is expected to launch in Japan in Q4 2024 Tokyo, Japan and Cambridge, UK, 5 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces randomization of the first patient in a Phase 3 clinical trial evaluating daridorexant, its n

GlobeNewswire 4 months ago

SOLTF
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). The collaboration combines Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-s

GlobeNewswire 5 months ago

SOLTF
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024

Tokyo, Japan and Cambridge, UK, 1 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended on 30 September 2024. The full report can be viewed here. Chris Cargill, President & CEO of Nxera, commented: “The third quarter of 2024 has seen Nxera reach two important product development milestones. First, i

GlobeNewswire 5 months ago

SOLTF
Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024

Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024 held yesterday in Tokyo. The Citeline Japan Awards, the Japanese rendition of the prestigious global Scrip Awards, which have been running for 20 years, recognize outstanding advancements and innovations in

GlobeNewswire 5 months ago

SOLTF
Nxera Pharma to Host R&D Day 2024

Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event. Date: Wednesday, 6 November 2024 Time: 16:30 – 18:00 JST (7:30 – 9:00 GMT) Presenters: Chris Cargill, President and CEO Dr. Matt Barnes, Executive Officer, President of Nxera Pharma UK and Head of R&DDr. Makoto Sugita, Executive Officer, Chief Medical Officer (CMO) and President of Nxera Pharma JapanHironoshin Nomura, E

GlobeNewswire 6 months ago

SOLTF
Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan

Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of global pharmaceutical companies Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Dr. Makoto Sugita, M.D., Ph.D., MBA, as President of Nxera Pharma Japan, and Exec

GlobeNewswire 6 months ago

SOLTF
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan

QUVIVIQ™ is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Nxera Pharma Japan Co., Ltd. (“NPJ”) has entered a new commercial partnership agreement with Shionogi & Co., Ltd. (“Shionogi”), regarding the distribution and sales for QU

GlobeNewswire 6 months ago

SOLTF
Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia

The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary endpointsPlans to make QUVIVIQ available as soon as possible to insomnia patients in Japan are underway Tokyo, Japan and Cambridge, UK, 24 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Nxera Pharma Japan Co

GlobeNewswire 6 months ago

SOLTF
Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapiesCancer Research UK’s Centre for Drug Development is sponsoring and managing the ongoing Phase 1/2a clinical trial of HTL0039732 Tokyo, Japan and Cambridge and London, UK, 13 September 2024 – Nxera Pharma (TSE: 4565, “Nxera”) and Cancer Research UK announce an upcoming presentation on the ongoing Phase 1/2a clinical trial (NCT05944

GlobeNewswire 7 months ago

SOLTF
Nxera Pharma’s Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

ORX750 showed clinically meaningful and statistically significant improvements in mean sleep latency and had a favorable safety and tolerability profile with no observations of frequently reported adverse eventsCentessa plans to rapidly advance ORX750 into Phase 2 studies beginning in the fourth quarter of 2024 Tokyo, Japan and Cambridge, UK, 11 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes the announcement

GlobeNewswire 7 months ago

SOLTF

Performance Overview

Return	JSS.DU	Nikkei 225 (^N225)
YTD	-14.52%	-12.17%
1-Year	-39.77%	-8.89%
3-Year	-45.08%	+29.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sosei Group Corp (JSS.DU)

Nxera Pharma Announces Appointments to its Executive Leadership Team

Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder

Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan

Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris

Nxera Pharma Proposes Changes to its Board of Directors

Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024

Nxera Pharma Webinar Presentation for FY2024 Financial Results

Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio

Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia

Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea

Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024

Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024

Nxera Pharma to Host R&D Day 2024

Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan

Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan

Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia

Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO

Nxera Pharma’s Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Performance Overview